For example, NCT04978675, a prospective trial conducted at MD Anderson Cancer Center, is assessing the use of rh PSMA 7.3 PET/MRI in detecting recurrent prostate cancer, as well as its effect on salvage RT planning. This evidence concerns the gene FOLH1 and prostate carcinoma.